Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis By Ogkologos - June 18, 2026 8 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SENTRY study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Two Separate Indications for fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Early-Stage Breast Cancer ESMO Calls for Further EU Measures Enhancing Europe’s Clinical Trial Regulatory Ecosystem Following Meeting of Health Ministers on 16 June 2026 ESMO Responds to Public Consultation on EU4Health Work Programme for 2027 and Highlights the Importance of Continuing Robust EU Support for Europe’s Beating Cancer... MOST POPULAR Therapy Rottweiler, known as Dogtor Loki, Is Delivering ‘Hero Healing Kits’... April 16, 2020 Teen’s Innovative “SMART Armour” Protects Breast Cancer Patients from Radiation May 31, 2019 Apalutamide Plus ADT Demonstrates a Rapid, Deep, and Durable PSA Decline... March 29, 2023 FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma July 31, 2020 Load more HOT NEWS ESMO’s Expert Consensus: Do Not Discontinue or Delay Cancer Treatment That... FDA Grants Regular Approval to Dostarlimab-gxly for dMMR Endometrial Cancer New on NCI’s Websites for March 2021 Research with integrity – why colour blindness is a research integrity...
